Palvella Therapeutics (PVLA) EPS (Weighted Average and Diluted) (2020 - 2026)
Palvella Therapeutics (PVLA) reported EPS (Weighted Average and Diluted) of -$1.2 for Q1 2026, down 62.16% year-over-year from -$3.17 in Q1 2025, and down 11.11% on a QoQ basis from -$1.08 in Q4 2025.
Palvella Therapeutics (PVLA) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.2 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 62.16% year-over-year to -$1.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.17 (up 40.68% YoY) and the FY2025 annual result came in at -$3.71, up 52.62% from the prior year.
- EPS (Weighted Average and Diluted) retreated to -$1.2 in Q1 2026 per PVLA's latest filing, from -$1.08 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $20.5 in Q4 2023 and bottomed at -$8.7 in Q3 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.94 (2025), against an average of $0.18.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) surged 2685.71%; it then tumbled 1000.0% in 2025.
- Tracing PVLA's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.14 in 2022, then jumped by 14742.86% to $20.5 in 2023, then slumped by 99.41% to $0.12 in 2024, then plunged by 1000.0% to -$1.08 in 2025, then dropped by 11.11% to -$1.2 in 2026.
- Per Business Quant, the three latest PVLA EPS (Weighted Average and Diluted) figures stand at -$1.2 (Q1 2026), -$1.08 (Q4 2025), and -$1.03 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -1.20 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.20 |
| Dec 31, 2025 | -1.08 |
| Sep 30, 2025 | -1.03 |
| Jun 30, 2025 | -0.86 |
| Mar 31, 2025 | -0.74 |
| Dec 31, 2024 | 0.12 |
| Sep 30, 2024 | -3.94 |
| Jun 30, 2024 | -2.47 |
| Mar 31, 2024 | -1.54 |
| Dec 31, 2023 | 20.50 |
| Sep 30, 2023 | -8.70 |
| Jun 30, 2023 | 3.62 |
| Jun 30, 2022 | -0.14 |
| Mar 31, 2022 | -0.07 |
| Dec 31, 2021 | -0.13 |
| Sep 30, 2021 | -0.24 |
| Jun 30, 2021 | -0.25 |
| Mar 31, 2021 | -0.07 |
| Dec 31, 2020 | -0.26 |
| Sep 30, 2020 | -0.26 |
| Jun 30, 2020 | -0.09 |